Safety Monitoring Activity During EGFR or Anaplastic Lymphoma Kinase Inhibitor Therapy for Patients With Lung Cancer.

MLA

Singh, Avani M., et al. “Safety Monitoring Activity During EGFR or Anaplastic Lymphoma Kinase Inhibitor Therapy for Patients With Lung Cancer.” JCO Oncology Practice, vol. 19, no. 6, June 2023, pp. 345–51. EBSCOhost, https://doi.org/10.1200/OP.22.00787.

APA

Singh, A. M., Rubiera-Pebe, R., Ahmad, Y., Shafique, M., Hicks, J. K., & Tanvetyanon, T. (2023). Safety Monitoring Activity During EGFR or Anaplastic Lymphoma Kinase Inhibitor Therapy for Patients With Lung Cancer. JCO Oncology Practice, 19(6), 345–351. https://doi.org/10.1200/OP.22.00787

Chicago

Singh, Avani M, Rafael Rubiera-Pebe, Yaser Ahmad, Michael Shafique, J Kevin Hicks, and Tawee Tanvetyanon. 2023. “Safety Monitoring Activity During EGFR or Anaplastic Lymphoma Kinase Inhibitor Therapy for Patients With Lung Cancer.” JCO Oncology Practice 19 (6): 345–51. doi:10.1200/OP.22.00787.